CTNNB1 and prostate carcinoma: For instance, the PNPCa PDX model derived from a treatment naïve soft tissue metastatic prostate cancer sample is reported to carry truncating mutations in RNF43 and APC, while the bone-metastatic prostate cancer PDX model LAPC9 has mutations in both APC and CTNNB1 (missense variation and in-frame insertion, respectively) [205].